'Michael D Hughes' хайлтад зориулсан 27-н үр дүнгүүд 1 - 20-г харуулж байна, асуулгын хугацаа: 0.07s
Үр дүнг сайжруулах
-
1
-
2
Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials -н McNeil Ngongondo, Justin Ritz, Michael D. Hughes, Mitch Matoga, Mina C. Hosseinipour
Хэвлэсэн 2024-01-01
Өгүүллэг -
3
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infecte... -н Amita Gupta, Michael D Hughes, Anthony J Garcia-Prats, Katherine McIntire, Anneke C Hesseling
Хэвлэсэн 2019-08-01
Өгүүллэг -
4
Statistical methodologies for evaluation of the rate of persistence of Ebola virus in semen of male survivors in Sierra Leone -н Ndema Habib, Michael D. Hughes, Nathalie Broutet, Anna Thorson, Philippe Gaillard, Sihem Landoulsi, Suzanne L. R. McDonald, Pierre Formenty
Хэвлэсэн 2022-01-01
Өгүүллэг -
5
-
6
Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines. -н Gbolahan Ajibola, Kara Bennett, Kathleen M Powis, Michael D Hughes, Jean Leidner, Samuel Kgole, Oganne Batlang, Mompati Mmalane, Joseph Makhema, Shahin Lockman, Roger Shapiro
Хэвлэсэн 2020-01-01
Өгүүллэг -
7
Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. -н Mary F Kearney, Jonathan Spindler, Ann Wiegand, Wei Shao, Richard Haubrich, Sharon Riddler, Christina M Lalama, Michael D Hughes, John M Coffin, John W Mellors
Хэвлэсэн 2018-01-01
Өгүүллэг -
8
Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience -н Sathya Narayanan, Nicholas K. Ngui, Ben Kinchington, Joseph Do Woong Choi, Thomas Michael D. Hughes, Josie Rutovitz, Csilla Hasovits, Kazi J. Nahar, Senarath Edirimanne, Gavin Marx
Хэвлэсэн 2024-06-01
Өгүүллэг -
9
Statistical methodologies for evaluation of the rate of persistence of Ebola virus in semen of male survivors in Sierra Leone. -н Ndema Habib, Michael D Hughes, Nathalie Broutet, Anna Thorson, Philippe Gaillard, Sihem Landoulsi, Suzanne L R McDonald, Pierre Formenty, Sierra Leone Ebola Virus Persistence Study Group
Хэвлэсэн 2022-01-01
Өгүүллэг -
10
Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials. -н McNeil Ngongondo, Justin Ritz, Michael D Hughes, Mitch Matoga, Mina C Hosseinipour, AIDS Clinical Trials Group A5208, A5221, A5175 and A5274 Study Teams
Хэвлэсэн 2024-01-01
Өгүүллэг -
11
Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants. -н Scott Dryden-Peterson, Oluwemimo Jayeoba, Michael D Hughes, Haruna Jibril, Kenneth McIntosh, Taolo A Modise, Aida Asmelash, Kathleen M Powis, Max Essex, Roger L Shapiro, Shahin Lockman
Хэвлэсэн 2013-01-01
Өгүүллэг -
12
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistanc... -н Robert A. Salata, Beatriz Grinsztejn, Justin Ritz, Ann C. Collier, Evelyn Hogg, Robert Gross, Catherine Godfrey, Nagalingeswaran Kumarasamy, Cecilia Kanyama, John W. Mellors, Carole L. Wallis, Michael D. Hughes, the ACTG A5288 Study Team
Хэвлэсэн 2023-01-01
Өгүүллэг -
13
Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana -н Kathleen M. Powis, Shahin Lockman, Gbolahan Ajibola, Michael D. Hughes, Kara Bennett, Jean Leidner, Oganne Batlang, Kerapetse Botebele, Sikhulile Moyo, Erik van Widenfelt, Joseph Makhema, Chipo Petlo, Haruna B. Jibril, Kenneth McIntosh, Max Essex, Roger L. Shapiro
Хэвлэсэн 2018-03-01
Өгүүллэг -
14
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. -н Athe M N Tsibris, Bette Korber, Ramy Arnaout, Carsten Russ, Chien-Chi Lo, Thomas Leitner, Brian Gaschen, James Theiler, Roger Paredes, Zhaohui Su, Michael D Hughes, Roy M Gulick, Wayne Greaves, Eoin Coakley, Charles Flexner, Chad Nusbaum, Daniel R Kuritzkes
Хэвлэсэн 2009-05-01
Өгүүллэг -
15
An augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV-infected pregnant women: a cluster randomized trial. -н Scott Dryden-Peterson, Kara Bennett, Michael D Hughes, Adrian Veres, Oaitse John, Rosina Pradhananga, Matthew Boyer, Carolyn Brown, Bright Sakyi, Erik van Widenfelt, Koona Keapoletswe, Madisa Mine, Sikhulile Moyo, Aida Asmelash, Mark Siedner, Mompati Mmalane, Roger L Shapiro, Shahin Lockman
Хэвлэсэн 2015-01-01
Өгүүллэг -
16
The statistical design and analysis of pandemic platform trials: Implications for the future – CORRIGENDUM -н Christopher J. Lindsell, Matthew Shotwell, Kevin J. Anstrom, Scott Berry, Erica Brittain, Frank E. Harrell, Nancy Geller, Birgit Grund, Michael D. Hughes, Prasanna Jagannathan, Eric Leifer, Carlee B. Moser, Karen L. Price, Michael Proschan, Thomas Stewart, Sonia Thomas, Giota Touloumi, Lisa LaVange
Хэвлэсэн 2024-01-01
Өгүүллэг -
17
The statistical design and analysis of pandemic platform trials: Implications for the future -н Christopher J. Lindsell, Matthew Shotwell, Kevin J. Anstrom, Scott Berry, Erica Brittain, Frank E. Harrell, Nancy Geller, Birgit Grund, Michael D. Hughes, Prasanna Jagannathan, Eric Leifer, Carlee B. Moser, Karen L. Price, Michael Proschan, Thomas Stewart, Sonia Thomas, Giota Touloumi, Lisa LaVange
Хэвлэсэн 2024-01-01
Өгүүллэг -
18
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. -н Tin Phan, Carolin Zitzmann, Kara W Chew, Davey M Smith, Eric S Daar, David A Wohl, Joseph J Eron, Judith S Currier, Michael D Hughes, Manish C Choudhary, Rinki Deo, Jonathan Z Li, Ruy M Ribeiro, Ruian Ke, Alan S Perelson, ACTIV-2/A5401 Study Team
Хэвлэсэн 2024-04-01
Өгүүллэг -
19
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies -н Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl
Хэвлэсэн 2025-03-01
Өгүүллэг -
20
ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic -н Maryam Keshtkar-Jahromi, Kevin J. Anstrom, Christina Barkauskas, Samuel M. Brown, Eric S. Daar, William Fischer, Kevin W. Gibbs, Elizabeth S. Higgs, Michael D. Hughes, Prasanna Jagannathan, Lisa LaVange, Christopher J. Lindsell, Seema U. Nayak, Roger Paredes, Mahesh Parmar, Ithan D. Peltan, Michael Proschan, Matthew S. Shotwell, David M. Vock, Tammy Yokum, Stacey J. Adam
Хэвлэсэн 2024-01-01
Өгүүллэг